NASDAQ · Biotechnology

GTBP (GTBP) Stock

$0.29 -4.65% NASDAQ: GTBP Healthcare

Valuation

MetricValue
Price$0.29
Market Cap$3.12M
P/E Ratio-0.07
P/B Ratio0.74
P/S Ratio0.00
EPS (TTM)$-6.25
52-Week High$3.85
52-Week Low$0.26
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-466.67%
ROA-350.00%
ROCE-200.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio4.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-58.0M$-21.0M$-14.0M$-14.0M$-12.0M
Net Profit$-58.0M$-21.0M$-8.0M$-13.0M$-28.0M
EPS$-2.06$-0.66$-5.64$-6.94$-6.25
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$32.0M$17.0M$14.0M$4.0M$8.0M
Total Liabilities$10.0M$5.0M$7.0M$6.0M$2.0M
Cash$9.0M$6.0M$1.0M$4.0M$7.0M
Borrowings$0$0$0$0$0

Latest News

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives GlobeNewswire · Jun 1, 2026 EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout Benzinga · Jun 1, 2026 GT Biopharma Reports First Quarter 2026 Financial Results GlobeNewswire · May 15, 2026 GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors GlobeNewswire · May 14, 2026 EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types Benzinga · May 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-16.0M$-15.0M$-9.0M$-13.0M$-13.0M
Investing Cash Flow$-23.0M$12.0M$-2.0M$13.0M$0
Financing Cash Flow$16.0M$0$0$0$0
Net Cash Flow$4.0M$-3.0M$-5.0M$3.0M$3.0M
Free Cash Flow$-16.0M$-15.0M$-9.0M$-13.0M$-13.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-295.93%
Quick Ratio3.69
Interest Coverage—
Return 1Y-82.48%
Return 3Y-96.50%
Return 5Y-99.90%

Ownership

Insiders Held5.81%
Institutions Held4.08%
Institutions Float Held4.33%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC451,8752026-03-31
Geode Capital Management, LLC294,4592026-03-31
Vanguard Fiduciary Trust Co225,9382026-03-31
Everhart Financial Group, Inc.100,0002026-06-30
Arax Advisory Partners93,6272026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARTL $0.77 +1.96% -0.12 $1.80M 0.00%
CARMCarisma Therapeutics, Inc. $0.01 -5.17% 0.01 $230148 0.00%
DRMA $1.10 -0.90% -0.15 $749713 0.00%
LIPOLipella Pharmaceuticals Inc. $0.07 +0.00% -0.05 $300354 0.00%
PBM $3.30 +4.76% 2.76 $62763 0.00%

About GTBP

GTBP is led by CEO Michael Martin Breen, employs 1 people, headquartered in US, publicly traded since 2018.

GTBP stock trades at $0.29 with a market capitalization of $3.12M. The stock is valued at a price-to-earnings (P/E) ratio of -0.07, price-to-book of 0.74, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.26 and $3.85, and currently trades 92.5% below its 52-week high.

On profitability, GTBP generates a return on equity (ROE) of -466.67%, return on capital employed of -200.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides